AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PGEN · NASDAQ · Biotechnology

Precigen

Commercializes PAPZIMEOS while developing selected gene and cell therapies.

$6.97

After-hours close+0.04 (+0.50%)

At close$6.94(−3.55%)

Something off on this page? Send us feedback.

Profile

Precigen, Inc.PGENHealth Care

Builds revenue around PAPZIMEOS, the FDA-approved treatment for adults with recurrent respiratory papillomatosis, as it moves into commercial operations. Selected programs in immuno-oncology, autoimmune disorders, and infectious diseases remain in development while resources are concentrated on the product launch.

Commercializes PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved, non-replicating adenoviral-vector immunotherapy for adults with recurrent respiratory papillomatosis. Administered by subcutaneous injection, the medicine marked the move from clinical development to commercial operations.

Develops gene- and cell-therapy programs through proprietary platforms across immuno-oncology, autoimmune disorders, and infectious diseases. Selected programs include PRGN-2009 and PRGN-3006, while enrollment in PRGN-3005 and PRGN-3007 was paused and UltraCAR-T spending was minimized.

Operates from Germantown, Maryland, and combined former business segments into one operating segment around the PAPZIMEOS launch. The business is shaped by commercialization of the approved medicine and the prioritization of resources among remaining development programs.

Company facts

CEOHelen Sabzevari, Ph.D.

ListedAug 8, 2013

ExchangeNASDAQ

HeadquartersGermantown, MD

CountryUnited States

Employees132

CIK0001356090

ISINUS74017N1054

Key statistics

Market cap$2.48B

EPS (ttm)−$1.14

P/E (ttm)−6.09

ROE-498.3%

P/B56.92

P/S28.91

Dividend yield—

Beta1.38vs XLV 0.70

Year to date +62.0% · Average volume (30d) 5.6M

Analysts

Price target, next 12 months$18.00+159.0%Median of 16 analysts · vs the Aug 28 close

ConsensusBuy11 of 16 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $6.95

High$18.00+159.0%

Median$18.00+159.0%

Low$18.00+159.0%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Aug 5, 2026	H.C. Wainwright	Reiterate		Buy	$14	$18
May 28, 2026	H.C. Wainwright	Target			$11	$14
May 14, 2026	H.C. Wainwright	Target			$6	$11
Aug 15, 2025	JP Morgan	Upgrade	Underweight	Neutral

Earnings

EPS

Estimate$0.09

ReportedDue Nov 12, 2026

Revenue

Estimate$69.2M

ReportedDue Nov 12, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 4, 2026Q2 FY26	−$0.01	$0.05	+514.3%	$28.0M	$55.0M	+96.5%	+5.51%
May 13, 2026Q1 FY26	−$0.03	−$0.02	+33.3%	$20.8M	$23.3M	+11.8%	+10.84%
Mar 25, 2026Q4 FY25	−$0.10	−$0.01	+90.0%	$8.4M	$4.6M	−45.6%	+25.48%
Nov 13, 2025Q3 FY25	−$0.08	−$0.11	−37.5%	$8.3M	$2.9M	−64.7%	+25.65%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$1.3M	$856.0K	$2.9M	$4.6M	$23.3M	$55.0M
Gross profit	−$78.0K	−$699.0K	$1.6M	$2.7M	$20.4M	$52.2M
Operating income	−$22.6M	−$31.8M	−$34.5M	−$21.7M	−$6.0M	$22.6M
Net income	−$54.2M	−$26.6M	−$146.3M	−$23.5M	−$7.9M	$20.1M
Diluted EPS	−$0.18	−$0.09	−$1.10	−$0.07	−$0.03	$0.05
Gross margin	-5.8%	-81.7%	53.7%	58.1%	87.6%	94.9%
Operating margin	-1,685.0%	-3,710.7%	-1,180.0%	-474.6%	-25.8%	41.2%

Fiscal years (4-quarter sums)FY21 $14.3M · FY22 $26.9M · FY23 $6.2M · FY24 $3.9M · FY25 $9.7M

Revenue by product · Q2 FY26

Product$53.3M · 97%

Service$1.7M · 3%

Revenue by geography · Q2 FY26

Non-US$165.0K · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $38.2M · Total debt $98.3M · Total assets $170.3M · Shareholders' equity $43.6M

Dividends

No dividends on record.

Ownership

Institutions 40.11%142.98M sharesInsiders 2.98%10.64M sharesOther 56.91%202.89M shares

Shares outstanding 356.51M · Float 159.28M · 44.7% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
William H. Miller III Living Trust dated April 17, 2017	34.05M	9.20%	13G	Sep 23, 2025
Patient Capital Management, LLC	19.04M	5.34%	13F	Aug 13, 2026
BlackRock, Inc.	17.15M	4.81%	13F	Aug 7, 2026
State Street Corp	12.00M	3.37%	13F	Aug 7, 2026
Diametric Capital, LP	9.27M	2.60%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 26, 2026	Jeffrey B. Kindler	director	−185,000	$7.44
Aug 21, 2026	Nancy H. Agee	director	+3,411	$7.23
Aug 25, 2026	Phil Tennant	officer: Chief Commercial Officer	−79,166	$7.50
Aug 25, 2026	Rutul R. Shah	officer: Chief Operating Officer	−15,342	$7.50
Aug 21, 2026	Rutul R. Shah	officer: Chief Operating Officer	−34,658	$7.50